Clinical Trials Directory

Trials / Completed

CompletedNCT01581411

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
1 (actual)
Sponsor
Weill Medical College of Cornell University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Central retinal vein occlusion (CRVO) is a common cause of vision loss, typically affecting individuals during the fifth through seventh decade of life. Eyes with severe CRVO have a poor visual prognosis because current treatments address only secondary complications of CRVO without treating its cause. Intra-ophthalmic artery injection of a small dose of t-PA (clot busting medicine), also called intra-ophthalmic artery thrombolysis, may reopen the central retinal vein-and address the cause of the disease- without exposing the subject to the risks of systemic thrombolysis. Our project aims to evaluate the safety and efficacy of intra-ophthalmic artery thrombolysis in subjects with CRVO.

Detailed description

1. Study hypothesis: Injection of t-PA, a thrombolytic drug (clot busting medicine)into the ophthalmic artery (the blood vessel feeding the eye), in patients with recent severe central retinal vein occlusion, may reopen the central retinal vein and improve retinal blood flow, which may in turn improve visual acuity and prevent the long-term complications of the disease. 2. Experimental intervention: An outpatient procedure during which the ophthalmic artery is selective catheterized (with a small plastic tube called a microcatheter introduced from the artery of the leg) and infused with t-PA during two hours.

Conditions

Interventions

TypeNameDescription
DRUGTissue Plasminogen ActivatorIntra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours

Timeline

Start date
2012-01-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2012-04-20
Last updated
2018-08-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01581411. Inclusion in this directory is not an endorsement.